Synchronised Cardiovascular Support Now Ready for the Market

Synchronised Cardiovascular Support Now Ready for the Market
share Share
Xenios AG concludes its first clinical study on i-cor Synchronized Cardiac Assist, documenting the safety and feasibility of the synchronized cardiovascular support system.

During the “SynCor” trial, a multicentre study treated 47 patients in nine different German clinics using an innovative pulsatile, cardiac-synchronous circulatory support system. The aim of the study was to collect prospective data on the performance and safety of i-cor Synchronized Cardiac Assist – a therapy mode of the CE-certified Xenios console. In the course of the study, 34 patients underwent cardiovascular therapy with i-cor due to a high-risk intervention on the coronary arteries while 13 patients were treated with i-cor due to cardiogenic shock.

Principal investigator Prof. Christoph Liebetrau from the Kerckhoff-Klinikum in Bad Nauheim presented the study results for the first time at the EURO PCR Congress in Paris on 22 May 2019. The results confirm that patients can be safely treated with i-cor Synchronized Cardiac Assist in both indication groups.

“Xenios AG would like to express its thanks to Prof. Liebetrau and all the centres that participated in this study. The results so far are reassuring, and they will have a significant role in advancing the development of cardiac-synchronous pulsatile circulatory support,” said PD Dr. Jürgen Böhm, Chief Medical Officer of Xenios AG.

The Synchritude Register, already in use in Germany, serves the purposes of post-market surveillance, helping collect additional prospective data on the performance of the i-cor Synchronized Cardiac Assist system in the context of combined heart-lung failure or high-risk interventions in the cardiac catheter laboratory.
Back to News

«« ICU Diaries Not Useful in Preventing PTSD Symptoms

Vitamin C Drug Cocktail for Sepsis »»

Published on : Wed, 10 Jul 2019

Related Articles
Merger: Novalung Becomes Fully Integrated within Xenios

Novalung GmbH, which specialises in solutions for respiratory failure, was absorbed into Xenios AG on 30 August 2019. Processes... Read more

Patient's healthcare

The US FDA (Food and Drug Administration) has granted 510(k) approval to Fresenius Medical Care North America and Xenios, a Fresenius... Read more

The Management Board of Xenios AG , the Heart & Lung Business Unit of Fresenius Medical Care, has been restructured. Effective... Read more

Cardiovascular, Xenios, i-cor Synchronized Cardiac Assist, synchronized cardiovascular support system, cardiovascular support system, SynCor trial Synchronised Cardiovascular Support Now Ready for the Market

No comment

Please login to leave a comment...

Highlighted Products